Back to Search
Start Over
Real-world evidence of brigatinib as second-line treatment after crizotinib for ALK+ non-small cell lung cancer using South Korean claims data (K-AREAL).
- Source :
-
Cancer medicine [Cancer Med] 2024 Jul; Vol. 13 (14), pp. e70030. - Publication Year :
- 2024
-
Abstract
- Purpose: There is a lack of real-world data in Asian populations for brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non-small cell lung cancer (NSCLC). This study analysed real-world outcomes and dosing patterns for brigatinib in patients with crizotinib-refractory ALK+ NSCLC in South Korea.<br />Methods: This retrospective, non-interventional, cohort study used South Korean Health Insurance and Review Assessment claims data for adults with ALK+ NSCLC who initiated brigatinib between 19 April 2019 and 31 March 2021 after receiving prior crizotinib. Patients' characteristics, time to discontinuation (TTD), time to dose reduction, overall survival (OS) and treatment adherence were assessed.<br />Results: The study included 174 patients (56.9% male; 27.0% with a history of brain metastases). Median duration of prior crizotinib was 17 (range 0.3-48) months. Median follow-up after brigatinib initiation was 18 (range 0-34) months. Overall, 88.5% of patients received full-dose brigatinib (180 mg/day) and 93.1% of patients were adherent (proportion of days covered ≥0.8). The median TTD was 24.9 months (95% CI 15.2-not reached). The probability of continuing treatment was 63.2% at 1 year and 51.5% at 2 years. The probability of continuing at full or peak dose was 79.7% at 1 year and 75.6% at 2 years. Median OS was not reached. The 2-year OS rate was 68.7%.<br />Conclusions: In this first nationwide retrospective study using national insurance claim data, brigatinib demonstrated real-world clinical benefit as second-line treatment after prior crizotinib in ALK+ NSCLC patients in South Korea.<br /> (© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
- Subjects :
- Humans
Male
Female
Republic of Korea
Middle Aged
Retrospective Studies
Adult
Aged
Protein Kinase Inhibitors therapeutic use
Treatment Outcome
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung pathology
Carcinoma, Non-Small-Cell Lung mortality
Crizotinib therapeutic use
Lung Neoplasms drug therapy
Lung Neoplasms mortality
Lung Neoplasms pathology
Organophosphorus Compounds therapeutic use
Organophosphorus Compounds administration & dosage
Organophosphorus Compounds adverse effects
Anaplastic Lymphoma Kinase genetics
Anaplastic Lymphoma Kinase antagonists & inhibitors
Pyrimidines therapeutic use
Pyrimidines administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 2045-7634
- Volume :
- 13
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Cancer medicine
- Publication Type :
- Academic Journal
- Accession number :
- 39030811
- Full Text :
- https://doi.org/10.1002/cam4.70030